ClinicaliQ Trial Snapshot
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma — Recruiting • Phase I • Oncology • NCT05169515.
- What is being tested: Combination therapies pairing bispecific antibodies (mosunetuzumab or glofitamab) with cereblon E3 ligase modulators (CELMoDs: CC-220 and/or CC-99282) to evaluate safety, pharmacokinetics, and efficacy in B-cell non-Hodgkin lymphoma.
- Patient eligibility overview: Participants with confirmed B-cell NHL who meet specific disease stage and prior treatment criteria; exact eligibility depends on individual trial arms but typically includes relapsed/refractory disease or treatment-Phase Iïve cohorts.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.
Eligibility Snapshot
- : * Age >/= 18 years * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 * History of one of the following histologically documented hematologic malignancies that are expected to express the CD20 antigen: In the Dose Escalation phase, participants must have relapsed after or failed to respond to at least two prior lines of systemic therapy. In the Dose Expansion phase, participants with FL Grades 1-3a must have relapsed after or failed to respond to at least one prior line of systemic therapy and must require systemic therapy. Participants with DLBCL/transformed FL must have relapsed after or failed to respond to at least one prior systemic treatment regimen. * Participants with DLBCL/transformed FL who have received only one prior line of therapy must: Not be considered a candidate for autologous stem cell transplantation (ASCT) due to age, performance status, comorbidities and/or insufficient response to prior treatment, or have refused ASCT; or be ineligible for or unable to receive chimeric antigen receptor T-cell (CAR-T) therapy due to reasons defined by the protocol * Fluorodeoxyglucose-avid lymphoma (i.e. PET-positive lymphoma) * At least one bi-dimensionally measurable nodal lesion (> 1.5 cm in its largest dimension by diagnostic…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.